1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA(ct DNA)predicts efficacy of Buparlisib(BUP)plus Fulvestrant(FULV)in postmenopausal women with endocrine-resistant HR+/HER2–advance...1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA(ct DNA)predicts efficacy of Buparlisib(BUP)plus Fulvestrant(FULV)in postmenopausal women with endocrine-resistant HR+/HER2–advanced breast cancer(BC):First results from the randomized,phaseⅢBELLE-2trial[C].San Antonio Breast Cancer Symposium,2015,abst S6-01.展开更多
2016年乳腺癌在转化医学方面的进展,主要在三个方面:(1)基因组学进展;(2)三阴性乳腺癌(triple-negative breast cancer,TNBC)新的靶点;(3)免疫治疗新进展。1基因组学进展1.1问题一:我们对乳腺癌细胞的基因全景了解足够全面了...2016年乳腺癌在转化医学方面的进展,主要在三个方面:(1)基因组学进展;(2)三阴性乳腺癌(triple-negative breast cancer,TNBC)新的靶点;(3)免疫治疗新进展。1基因组学进展1.1问题一:我们对乳腺癌细胞的基因全景了解足够全面了么?Nik-Zainal等[1]2016年发表在《Nature》上的一篇文章,对560位乳腺癌患者进行了全基因组测序,展开更多
1文献来源Cristofanilli M,Turner NC,Bondarenko I,et al.Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptorpositive,HER2-negative metastatic breast cancer that progressed on pr...1文献来源Cristofanilli M,Turner NC,Bondarenko I,et al.Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptorpositive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016,17(4):425-439.展开更多
世界卫生组织国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了2020年全球最新癌症数据。全球乳腺癌新发病例高达226万例,超过了肺癌220万例,成为全球第一大癌。中国乳腺癌防治事业仍然任重道远,要实现健康...世界卫生组织国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了2020年全球最新癌症数据。全球乳腺癌新发病例高达226万例,超过了肺癌220万例,成为全球第一大癌。中国乳腺癌防治事业仍然任重道远,要实现健康中国目标,应重视乳腺癌的早期诊断、精准综合治疗和重要临床研究。乳腺癌诊疗水平越来越高,5年生存率可达90%[1]。展开更多
1文献来源L■nkholm AV,Jensen MB,Eriksen JO,et al.PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy fo...1文献来源L■nkholm AV,Jensen MB,Eriksen JO,et al.PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer[J]. J Clin Oncol,2018,36(8):735-740.2证据水平1b。展开更多
1文献来源Park JW,Liu MC,Yee D,et al. Adaptive randomization of Neratinib in early breast cancer[J].N Eng J Med,2016,375(1):11-22.2证据水平1b。3背景·肿瘤异质性使确定乳腺癌最佳疗法具有挑战性。·新辅助化疗所能...1文献来源Park JW,Liu MC,Yee D,et al. Adaptive randomization of Neratinib in early breast cancer[J].N Eng J Med,2016,375(1):11-22.2证据水平1b。3背景·肿瘤异质性使确定乳腺癌最佳疗法具有挑战性。·新辅助化疗所能达到的替代终点--病理完全缓解率(pathologic complete response,pCR)成为靶向治疗得以快速发展的重要原因.展开更多
1文献来源Cardoso F,van.t Veer LJ,Bogaerts J,et al. 70-gene signature as an aid to treatment decisions inearly-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.2证据水平1b。3背景70基因检测(MammaPrint)是来自荷...1文献来源Cardoso F,van.t Veer LJ,Bogaerts J,et al. 70-gene signature as an aid to treatment decisions inearly-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.2证据水平1b。3背景70基因检测(MammaPrint)是来自荷兰癌症研究院的研究者开发的一套乳腺癌多基因检测系统,在5年和10年远处复发风险基础上,根据基因表达与临床结果的相关性,将患者分为预后良好组及预后不良组,并且已有多项回顾性研究证实了MammaPrint 70基因检测对早期乳腺癌患者预后的预测作用.但目前尚缺乏前瞻性评价MammaPrint 70基因检测对化疗决策影响的临床试验.展开更多
文摘1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA(ct DNA)predicts efficacy of Buparlisib(BUP)plus Fulvestrant(FULV)in postmenopausal women with endocrine-resistant HR+/HER2–advanced breast cancer(BC):First results from the randomized,phaseⅢBELLE-2trial[C].San Antonio Breast Cancer Symposium,2015,abst S6-01.
文摘2016年乳腺癌在转化医学方面的进展,主要在三个方面:(1)基因组学进展;(2)三阴性乳腺癌(triple-negative breast cancer,TNBC)新的靶点;(3)免疫治疗新进展。1基因组学进展1.1问题一:我们对乳腺癌细胞的基因全景了解足够全面了么?Nik-Zainal等[1]2016年发表在《Nature》上的一篇文章,对560位乳腺癌患者进行了全基因组测序,
文摘1文献来源Cristofanilli M,Turner NC,Bondarenko I,et al.Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptorpositive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016,17(4):425-439.
文摘世界卫生组织国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了2020年全球最新癌症数据。全球乳腺癌新发病例高达226万例,超过了肺癌220万例,成为全球第一大癌。中国乳腺癌防治事业仍然任重道远,要实现健康中国目标,应重视乳腺癌的早期诊断、精准综合治疗和重要临床研究。乳腺癌诊疗水平越来越高,5年生存率可达90%[1]。
文摘1文献来源L■nkholm AV,Jensen MB,Eriksen JO,et al.PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer[J]. J Clin Oncol,2018,36(8):735-740.2证据水平1b。
文摘1文献来源Park JW,Liu MC,Yee D,et al. Adaptive randomization of Neratinib in early breast cancer[J].N Eng J Med,2016,375(1):11-22.2证据水平1b。3背景·肿瘤异质性使确定乳腺癌最佳疗法具有挑战性。·新辅助化疗所能达到的替代终点--病理完全缓解率(pathologic complete response,pCR)成为靶向治疗得以快速发展的重要原因.
文摘1文献来源Cardoso F,van.t Veer LJ,Bogaerts J,et al. 70-gene signature as an aid to treatment decisions inearly-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.2证据水平1b。3背景70基因检测(MammaPrint)是来自荷兰癌症研究院的研究者开发的一套乳腺癌多基因检测系统,在5年和10年远处复发风险基础上,根据基因表达与临床结果的相关性,将患者分为预后良好组及预后不良组,并且已有多项回顾性研究证实了MammaPrint 70基因检测对早期乳腺癌患者预后的预测作用.但目前尚缺乏前瞻性评价MammaPrint 70基因检测对化疗决策影响的临床试验.